Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study
Abstract Background Recently, chemotherapy plus immunotherapy has achieved remarkable efficacy in lung squamous cell carcinoma (LUSC). However, some patients, especially frail people, cannot tolerate full‐dose chemotherapy in the real world. To reduce toxicity, appropriate dose reduction in chemothe...
Main Authors: | Ganlu Ouyang, Yanyang Liu, Jiewei Liu, Lin Huang, Feng Luo, Lu Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6478 |
Similar Items
-
Low-Dose Immunotherapy: Is It Just an Illusion?
by: Fausto Meriggi, et al.
Published: (2023-03-01) -
Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma
by: Yanfei Hao, et al.
Published: (2024-05-01) -
Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)
by: Wonjun Ji, et al.
Published: (2023-11-01) -
Chemotherapy: A partnership with immunotherapy in non‐small cell lung cancer
by: Ana Sofia Mendes, et al.
Published: (2023-02-01) -
Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
by: Min Fang, et al.
Published: (2023-01-01)